涤痰降压方加减治疗痰热上扰型原发性高血压患者的回顾性分析
Retrospective Analysis of Modified Ditan Jiangya Decoction in the Treatment of Essential Hypertension with Phlegm-Heat Disturbing the Upper Orifices Pattern
DOI: 10.12677/acm.2026.1672722, PDF,   
作者: 吕芝延*:黑龙江中医药大学研究生院,黑龙江 哈尔滨;黑龙江中医药大学附属第二医院心血管一科,黑龙江 哈尔滨;张鸿婷#:黑龙江中医药大学附属第二医院心血管一科,黑龙江 哈尔滨
关键词: 涤痰降压方痰热上扰型原发性高血压回顾性分析Ditan Jiangya Decoction Phlegm-Heat Disturbing the Upper Orifices Pattern Essential Hypertension Retrospective Analysis
摘要: 目的:探讨涤痰降压方联合常规降压药治疗痰热上扰型原发性高血压的临床疗效,为中西医结合治疗该类型高血压提供循证依据。方法:回顾性收集2020年2月至2024年8月就诊于黑龙江中医药大学附属第二医院心血管一科的132例痰热上扰型原发性高血压患者,按治疗方案分为治疗组(65例,常规降压药 + 涤痰降压方)与对照组(67例,单纯常规降压药)。治疗4周后,比较两组中医证候积分、诊室血压、24 h动态血压及临床疗效。结果:治疗后,两组患者中医证候总积分均显著下降(P < 0.05),且治疗组(5.80 ± 4.848)低于对照组(14.81 ± 8.628),治疗组中医证候总有效率(89.23%)高于对照组(59.70%) (P < 0.05);两组诊室收缩压、舒张压均明显降低(P < 0.05),治疗组降压总有效率(86.67%)高于对照组(68.66%) (P < 0.05);治疗组24 h动态平均血压、日间及夜间平均血压、动态脉压、血压负荷、血压变异系数等指标改善幅度均优于对照组(P < 0.05)。结论:涤痰降压方联合常规降压药治疗痰热上扰型原发性高血压,能更显著降低患者血压水平,改善中医证候及动态血压相关指标,临床疗效确切。
Abstract: Objective: To explore the clinical efficacy of Ditan Jiangya Decoction combined with conventional antihypertensive drugs in the treatment of essential hypertension with phlegm-heat disturbing the upper orifices pattern, and to provide evidence-based basis for integrated traditional Chinese and Western medicine in the treatment of this type of hypertension. Methods: A retrospective collection was conducted on 132 patients with essential hypertension of phlegm-heat disturbing the upper orifices pattern who were admitted to the First Department of Cardiovascular Medicine, the Second Affiliated Hospital of Heilongjiang University of Chinese Medicine from February 2020 to August 2024. They were divided into the treatment group (65 cases, conventional antihypertensive drugs + Ditan Jiangya Decoction) and the control group (67 cases, conventional antihypertensive drugs alone) according to the treatment plan. After 4 weeks of treatment, the TCM syndrome scores, office blood pressure, 24-hour ambulatory blood pressure and clinical efficacy were compared between the two groups. Results: After treatment, the total TCM syndrome scores of both groups decreased significantly (P < 0.05), and the treatment group (5.80 ± 4.848) was lower than the control group (14.81 ± 8.628). The total effective rate of TCM syndrome in the treatment group (89.23%) was higher than that in the control group (59.70%) (P < 0.05). The office systolic blood pressure and diastolic blood pressure in both groups were significantly reduced (P < 0.05), and the total antihypertensive effective rate in the treatment group (86.67%) was higher than that in the control group (68.66%) (P < 0.05). The improvement of 24-hour ambulatory mean blood pressure, daytime and nighttime mean blood pressure, ambulatory pulse pressure, blood pressure load, blood pressure variability coefficient and other indicators in the treatment group was superior to that in the control group (P < 0.05). Conclusion: Ditan Jiangya Decoction combined with conventional antihypertensive drugs in the treatment of essential hypertension with phlegm-heat disturbing the upper orifices pattern can more significantly reduce the patient’s blood pressure level, improve TCM syndromes and ambulatory blood pressure-related indicators, with definite clinical efficacy.
文章引用:吕芝延, 张鸿婷. 涤痰降压方加减治疗痰热上扰型原发性高血压患者的回顾性分析[J]. 临床医学进展, 2026, 16(7): 1961-1970. https://doi.org/10.12677/acm.2026.1672722

参考文献

[1] 张开泰, 周静静, 宋彦洁, 等. 化痰解郁安神方联合常规西药治疗痰湿中阻型原发性高血压伴焦虑症的临床观察[J]. 中药材, 2025, 48(9): 2362-2365.
[2] Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., et al. (2018) 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension. European Heart Journal, 39, 3021-3104. [Google Scholar] [CrossRef] [PubMed]
[3] Wu, Y., Jin, A., Xie, G., Wang, L., Liu, K., Jia, G., et al. (2018) The 20 Most Important and Most Preventable Health Problems of China: A Delphi Consultation of Chinese Experts. American Journal of Public Health, 108, 1592-1598. [Google Scholar] [CrossRef] [PubMed]
[4] 中国高血压防治指南修订委员会, 高血压联盟(中国), 中国医疗保健国际交流促进会高血压病学分会, 等. 中国高血压防治指南(2024年修订版) [J]. 中华高血压杂志(中英文), 2024, 32(7): 603-700.
[5] 孟醒, 熊兴江. 初发高血压病、青年高血压病的中医认识及天麻钩藤饮的临床治疗体会[J]. 中国中药杂志, 2020, 45(12): 2752-2759.
[6] 赵连友, 李妍, 牛晓琳, 等. 对我国高血压防控策略的思考[J]. 中华高血压杂志, 2024, 32(1): 2-5.
[7] 《中国心血管健康与疾病报告2022》编写组.《中国心血管健康与疾病报告2022》要点解读[J]. 中国心血管杂志, 2023, 28(4): 297-312.
[8] 刘海伦, 周婧彧, 郑静静, 等. 高血压非药物治疗研究进展[J]. 中华高血压杂志, 2023, 31(11): 1117-1123.
[9] 熊兴江, 王阶. 经方在高血压病治疗中的运用[J]. 中国中药杂志, 2013, 38(11): 1836-1839.
[10] 唐补生, 曹敏, 李广浩, 等. 血压难控因素的中医辨识和治疗[J]. 辽宁中医杂志, 2009, 36(2): 197-198.
[11] McNair, D., Lumpkin, M., Kern, S. and Hartman, D. (2022) Use of RWE to Inform Regulatory, Public Health Policy, and Intervention Priorities for the Developing World. Clinical Pharmacology & Therapeutics, 111, 44-51. [Google Scholar] [CrossRef] [PubMed]
[12] Honig, P.K. (2022) The “Coming of Age” of Real‐World Evidence in Drug Development and Regulation. Clinical Pharmacology & Therapeutics, 111, 11-14. [Google Scholar] [CrossRef] [PubMed]
[13] Sun, X., Tan, J., Tang, L., Guo, J.J. and Li, X. (2018) Real World Evidence: Experience and Lessons from China. BMJ, 360, j5262. [Google Scholar] [CrossRef] [PubMed]
[14] 周雪忠, 王世华, 张迪, 等. 构建中医药特色真实世界临床研究新模式的实践与思考[J]. 科技导报, 2023, 41(14): 22-31.
[15] 熊兴江, 王阶. 论高血压病的中医认识及经典名方防治策略[J]. 中医杂志, 2011, 52(23): 1985-1989.
[16] 姜铭, 姚锐, 袁维运. 针刺联合六味地黄丸加味干预老年卒中伴高血压(肝肾阴虚型)的临床观察及对血压水平影响[J]. 中华中医药学刊, 2026, 44(3): 180-184.
[17] 马振庆, 肇启新. 东北人性格特征与油画风景的地域性[J]. 黑龙江民族丛刊, 2016(2): 159-162.
[18] 国家中医药管理局. 中医病证诊断疗效标准: ZY/T 001.1~001.9-94 [S]. 南京: 南京大学出版社, 1994: 23.
[19] 郑筱萸. 中药新药临床研究指导原则(试行) [M]. 北京: 中国医药科技出版社, 2002.
[20] 姜德友, 周雪明. 眩晕病源流考[J]. 中医文献杂志, 2011, 29(1): 10.
[21] 孟醒, 熊兴江.《高血压中医诊疗专家共识》解读[J]. 中国实验方剂学杂志, 2022, 28(11): 192-205.
[22] 高血压中医诊疗专家共识[J]. 中国实验方剂学杂志, 2019, 25(15): 217-221.
[23] Kario, K. (2013) Orthostatic Hypertension—A New Haemodynamic Cardiovascular Risk Factor. Nature Reviews Nephrology, 9, 726-738. [Google Scholar] [CrossRef] [PubMed]
[24] 傅为武, 欧阳雅蓉, 黄彩依, 等. 基于高血压炎症反应探讨高血压治疗研究进展[J]. 海南医学院学报, 2021, 27(9): 717-720.
[25] 黄琼, 詹文凤, 刘希奇, 等. 清眩降压汤治疗肝阳上亢型高血压病并失眠患者的临床研究[J]. 时珍国医国药, 2025, 36(21): 4101-4108.
[26] Costa, R.M., Cerqueira, D.M., Bruder-Nascimento, A., Alves, J.V., Awata, W.M.C., Singh, S., et al. (2024) Role of the CCL5 and Its Receptor, CCR5, in the Genesis of Aldosterone-Induced Hypertension, Vascular Dysfunction, and End-Organ Damage. Hypertension, 81, 776-786. [Google Scholar] [CrossRef] [PubMed]
[27] 袁钊, 苏海. 高血压初始治疗使用国产小剂量复方制剂是否合理? [J]. 中华高血压杂志(中英文), 2025, 33(1): 2-3.
[28] 张裕. “活血散风”针刺法对正常高值血压人群临床症状及血管功能的影响[D]: [硕士学位论文]. 北京: 北京中医药大学, 2023.
[29] 羊田, 吴新萍, 万文洲. 半夏白术天麻汤治疗痰湿中阻型原发性高血压的临床效果及安全性分析[J]. 深圳中西医结合杂志, 2025, 35(9): 71-73+77.
[30] 张澎, 苏发智, 朱恩琳, 等. 基于肠道菌群及代谢组学探讨胆南星的降血脂作用机制[J]. 中国中药杂志, 2025, 50(6): 1544-1557.
[31] 唐照琦, 李彪, 王秋红, 等. 胆南星的化学成分、药理作用及相关复方临床应用的研究进展[J]. 中国药房, 2020, 31(12): 1523-1527.
[32] Jie, L.H., Jantan, I., Yusoff, S., et al. (2021) Sinensetin: An Insight on Its Pharmacological Activities, Mechanisms of Action and Toxicity. Frontiers in Pharmacology, 11, Article ID: 553404. [Google Scholar] [CrossRef] [PubMed]
[33] 吴倩颖, 刘德鸿, 陈伟康, 等. 不同基原枳实的多组分含量测定及差异性成分分析[J]. 中国药房, 2025, 36(9): 1071-1075.
[34] 王家豪, 花海兵, 薛昊, 等. 古代经典名方温胆汤的研究进展及质量标志物的预测分析[J]. 世界科学技术-中医药现代化, 2024, 26(6): 1528-1536.
[35] 柳威. 茯苓及其有效成分药理作用机理研究进展[J]. 山西中医, 2025, 41(10): 64-67.
[36] 李鹏辉, 孙瑜, 冯小龙, 等. 石菖蒲抗癫痫的药理机制研究进展[J]. 中国实验方剂学杂志, 2022, 28(18): 261-268.
[37] 乐颖娜, 张金莲, 钟凌云, 等. 石菖蒲炮制的历史沿革、化学成分及神经药理作用研究进展[J]. 中草药, 2025, 56(11): 4115-4127.
[38] 赵学敏. 本草纲目拾遗[M]. 刘从明, 校注. 北京: 中医古籍出版社, 2017: 194.
[39] 李孟, 郭梦真, 王小兰, 等. 怀菊花干预动脉粥样硬化的药效物质基础研究[J]. 时珍国医国药, 2025, 36(7): 1383-1391.
[40] Yuan, H., Jiang, S., Liu, Y., Daniyal, M., Jian, Y., Peng, C., et al. (2020) The Flower Head of Chrysanthemum Morifolium Ramat. (Juhua): A Paradigm of Flowers Serving as Chinese Dietary Herbal Medicine. Journal of Ethnopharmacology, 261, Article 113043. [Google Scholar] [CrossRef] [PubMed]
[41] 邓晓颜, 王小兰, 李孟, 等. 怀菊花总黄酮富集纯化工艺优化及其抗炎活性、成分组成研究[J]. 中成药, 2023, 45(9): 2815-2821.
[42] 陈明龙, 覃桂, 张兴明, 等. 基于文献计量学的夏枯草植物学特性、种植管理及药理作用研究进展[J]. 中草药, 2025, 56(16): 6017-6029.
[43] 王梅, 曹春琪, 雷蓉, 等. 黄芩有效成分及外源性污染物的质量评价研究进展[J/OL]. 中华中医药学刊, 2025: 1-16.
https://link.cnki.net/urlid/21.1546.R.20250912.1304.022, 2026-07-13.
[44] 白宇鑫, 马红丽, 王宇, 等. 桑寄生活性成分、药理作用及妇科临床应用研究进展[J]. 中华中医药学刊, 2026, 44(5): 172-176.
[45] 郭遂怀, 张鹏, 陈爱春, 等. 涤痰汤对动脉粥样硬化兔模型炎性细胞因子的相关研究[J]. 中华中医药学刊, 2017, 35(5): 1306-1309, 1367-1368.
[46] 陆彭, 康达, 刘洺岐, 等. 牛膝白芍颗粒配伍对肝阳上亢型高血压肾损伤的保护作用[J]. 中国临床药理学杂志, 2024, 40(22): 3285-3289.